Details
| Original language | English |
|---|---|
| Pages (from-to) | 129-134 |
| Number of pages | 6 |
| Journal | Prostaglandins Leukotrienes and Essential Fatty Acids |
| Volume | 91 |
| Issue number | 4 |
| Publication status | Published - 1 Oct 2014 |
Abstract
INTRODUCTION: Ingestion of long-chain n-3 PUFA effectively decreases serum triacylglycerol (TAG) levels and increases the Omega-3 Index, defined as the % of EPA and DHA in erythrocyte fatty acids. However, it remains unclear whether there is a relationship between the Omega-3 Index increase (ΔO3I increase) and the TAG level decrease (ΔTAG). We hypothesized that TAG reduction is strongly depended on Omega-3 Index increase.
SUBJECTS AND METHODS: Secondary analyses of data from a former double-blind placebo-controlled trial in which 150 dyslipidemic statin-treated subjects were randomized to four capsules of fish oil daily either as re-esterified TAG or ethyl esters in identical doses (1.01 g EPA+0.67 g DHA) or corn oil as a placebo for a period of six month.
RESULTS: 108 subjects fulfilled the criteria of the current study protocol and were included in the analyses. A weak but significant negative correlation between ΔO3I and ΔTAG was observed (r=-0.211, p<0.05). However, the relation between ΔO3I and serum ΔTAG was not linear (coefficients of determination R(2): 0.044). After sub-grouping the study population into Omega-3 Index response groups, the group with a mean ΔO3I of>4% after six months of n-3 PUFA treatment demonstrated the greatest TAG reduction.
DISCUSSION AND CONCLUSIONS: A weak association between Omega-3 Index increase and TAG level decrease was found. This may be explained by highly fluctuating TAG levels, a large inter-individual difference in response of the Omega-3 Index, a cohort of subjects with only slightly elevated TAG levels and high Omega-3 Index values at baseline, and possibly to insufficient statistical power. Since there was no strong association between Omega-3 Index increase and the TAG level decrease, we conclude that changes in serum TAG levels are not a viable substitute for the Omega-3 Index to monitor treatment with EPA and DHA.
Keywords
- Aged, Dietary Supplements, Docosahexaenoic Acids/therapeutic use, Double-Blind Method, Eicosapentaenoic Acid/therapeutic use, Fatty Acids, Omega-3/blood, Female, Humans, Hypertriglyceridemia/blood, Male, Middle Aged, Triglycerides/blood, Triacylglycerides, Omega-3 Index, Hypertriglyceridemia
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
- Clinical Biochemistry
- Biochemistry, Genetics and Molecular Biology(all)
- Cell Biology
Cite this
- Standard
- Harvard
- Apa
- Vancouver
- BibTeX
- RIS
In: Prostaglandins Leukotrienes and Essential Fatty Acids, Vol. 91, No. 4, 01.10.2014, p. 129-134.
Research output: Contribution to journal › Article › Research › peer review
}
TY - JOUR
T1 - Associations between Omega-3-Index increase and triacylglyceride decrease in subjects with hypertriglyceridemia in response to six month of EPA and DHA supplementation
AU - Schuchardt, Jan Philipp
AU - Neubronner, Juliane
AU - Block, Robert C
AU - von Schacky, Clemens
AU - Hahn, Andreas
N1 - Publisher Copyright: Copyright © 2014. Published by Elsevier Ltd. Copyright: This record is sourced from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PY - 2014/10/1
Y1 - 2014/10/1
N2 - INTRODUCTION: Ingestion of long-chain n-3 PUFA effectively decreases serum triacylglycerol (TAG) levels and increases the Omega-3 Index, defined as the % of EPA and DHA in erythrocyte fatty acids. However, it remains unclear whether there is a relationship between the Omega-3 Index increase (ΔO3I increase) and the TAG level decrease (ΔTAG). We hypothesized that TAG reduction is strongly depended on Omega-3 Index increase.SUBJECTS AND METHODS: Secondary analyses of data from a former double-blind placebo-controlled trial in which 150 dyslipidemic statin-treated subjects were randomized to four capsules of fish oil daily either as re-esterified TAG or ethyl esters in identical doses (1.01 g EPA+0.67 g DHA) or corn oil as a placebo for a period of six month.RESULTS: 108 subjects fulfilled the criteria of the current study protocol and were included in the analyses. A weak but significant negative correlation between ΔO3I and ΔTAG was observed (r=-0.211, p<0.05). However, the relation between ΔO3I and serum ΔTAG was not linear (coefficients of determination R(2): 0.044). After sub-grouping the study population into Omega-3 Index response groups, the group with a mean ΔO3I of>4% after six months of n-3 PUFA treatment demonstrated the greatest TAG reduction.DISCUSSION AND CONCLUSIONS: A weak association between Omega-3 Index increase and TAG level decrease was found. This may be explained by highly fluctuating TAG levels, a large inter-individual difference in response of the Omega-3 Index, a cohort of subjects with only slightly elevated TAG levels and high Omega-3 Index values at baseline, and possibly to insufficient statistical power. Since there was no strong association between Omega-3 Index increase and the TAG level decrease, we conclude that changes in serum TAG levels are not a viable substitute for the Omega-3 Index to monitor treatment with EPA and DHA.
AB - INTRODUCTION: Ingestion of long-chain n-3 PUFA effectively decreases serum triacylglycerol (TAG) levels and increases the Omega-3 Index, defined as the % of EPA and DHA in erythrocyte fatty acids. However, it remains unclear whether there is a relationship between the Omega-3 Index increase (ΔO3I increase) and the TAG level decrease (ΔTAG). We hypothesized that TAG reduction is strongly depended on Omega-3 Index increase.SUBJECTS AND METHODS: Secondary analyses of data from a former double-blind placebo-controlled trial in which 150 dyslipidemic statin-treated subjects were randomized to four capsules of fish oil daily either as re-esterified TAG or ethyl esters in identical doses (1.01 g EPA+0.67 g DHA) or corn oil as a placebo for a period of six month.RESULTS: 108 subjects fulfilled the criteria of the current study protocol and were included in the analyses. A weak but significant negative correlation between ΔO3I and ΔTAG was observed (r=-0.211, p<0.05). However, the relation between ΔO3I and serum ΔTAG was not linear (coefficients of determination R(2): 0.044). After sub-grouping the study population into Omega-3 Index response groups, the group with a mean ΔO3I of>4% after six months of n-3 PUFA treatment demonstrated the greatest TAG reduction.DISCUSSION AND CONCLUSIONS: A weak association between Omega-3 Index increase and TAG level decrease was found. This may be explained by highly fluctuating TAG levels, a large inter-individual difference in response of the Omega-3 Index, a cohort of subjects with only slightly elevated TAG levels and high Omega-3 Index values at baseline, and possibly to insufficient statistical power. Since there was no strong association between Omega-3 Index increase and the TAG level decrease, we conclude that changes in serum TAG levels are not a viable substitute for the Omega-3 Index to monitor treatment with EPA and DHA.
KW - Aged
KW - Dietary Supplements
KW - Docosahexaenoic Acids/therapeutic use
KW - Double-Blind Method
KW - Eicosapentaenoic Acid/therapeutic use
KW - Fatty Acids, Omega-3/blood
KW - Female
KW - Humans
KW - Hypertriglyceridemia/blood
KW - Male
KW - Middle Aged
KW - Triglycerides/blood
KW - Triacylglycerides
KW - Omega-3 Index
KW - Hypertriglyceridemia
UR - http://www.scopus.com/inward/record.url?scp=85027956310&partnerID=8YFLogxK
U2 - 10.1016/j.plefa.2014.07.014
DO - 10.1016/j.plefa.2014.07.014
M3 - Article
C2 - 25108576
VL - 91
SP - 129
EP - 134
JO - Prostaglandins Leukotrienes and Essential Fatty Acids
JF - Prostaglandins Leukotrienes and Essential Fatty Acids
SN - 0952-3278
IS - 4
ER -